"phase_id","region","country","location","sampleType","startDate","endDate","midpointDate","testTime","testName","citationID","nSeropositives","nSamples","sensitivityMean","sensitivityL","sensitivityH","includedTable","notes","timeKnown","antigenTarget","antibodyTarget","technique","design","validationGroup","predictedPos","predictedPosL","predictedPosH","sensitivityMeanPred","sensitivityMedianPred","sensitivityLPred","sensitivityHPred"
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",4.5,"Abbott Architect IgG","n-240",11,11,100,71.51,100,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect",77,9,6,11,83.0454274419102,83.826088934481,68.8212432054133,92.8559488303564
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*August 2020","*October 2020","*September 2020",5,"Abbott Architect IgG","n-133",64,109,58.72,48.88,68.06,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect",77,71,25,101,62.7003428624453,64.7826129586779,23.9585345528152,91.537900783141
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Abbott Architect IgG","n-132",81,144,56.2,48.2,64.7,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect",77,101,80,119,70.0474430724739,70.2991907005894,57.9347397803798,80.5326764127334
"3","South Asia","India","National","representative","--","--","12/27/2020",5,"Abbott Architect IgG","n-96",26,74,35.14,24.39,47.11,"Yes","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect",77,26,15,39,35.6467449405622,35.3918418728965,24.1134610526268,48.2363443501633
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",6,"Abbott Architect IgG","n-240",30,44,68.18,52.42,81.39,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect",77,34,22,41,75.8672401933832,77.0473146464064,54.6969470076912,90.7394252593056
"--","Europe","Germany","{ Saarland }","non-hospitalized patients","--","*October 2020","*October 2020",6,"Abbott Architect IgG","n-289",15,30,50,31.3,68.7,"Yes","figure 2g",TRUE,"N","IgG","CMIA","indirect",77,17,4,28,56.4640776937238,57.4427735763613,17.9549918560536,89.6986728722109
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Abbott Architect IgG","n-132",35,107,32.8,24.2,42.3,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect",77,61,36,83,56.6605624133223,56.9096749476055,36.1918779358399,75.4512342621875
"3","South Asia","India","National","representative","--","--","12/27/2020",7,"Abbott Architect IgG","n-96",6,23,26.09,10.23,48.41,"N","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect",77,5,1,11,24.1878192631034,23.3848301999546,11.6096895206737,40.8047881284463
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*January 2021","*March 2021","*February 2021",10,"Abbott Architect IgG","n-133",26,109,23.85,16.21,32.97,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect",77,32,4,87,33.2129195316192,29.7159091518413,4.59347380131447,78.6415700963577
"--","Oceania","New Zealand","{ Southern District Health Board region }","hospitalized + non-hospitalized patients","3/11/2020","4/5/2020","--",10,"Abbott Architect IgG","n-198",10,37,27.03,13.79,44.12,"Yes","",TRUE,"N","IgG","CMIA","indirect",77,11,1,30,33.4351007277526,29.8192155544794,4.46416289120904,78.5458447709219
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",4.5,"Abbott Architect IgG","n-89",10,14,71.43,41.9,91.61,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect",77,11,7,14,75.449520420567,75.8958689126643,62.022786070577,86.4746708143399
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Abbott Architect IgG","n-290",101,162,62.35,54.4,69.83,"","table 1",TRUE,"N","IgG","CMIA","indirect",77,129,106,145,79.0062923767152,79.4903781420553,67.2671795764469,87.9091623095737
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Abbott Architect IgG","n-290",41,95,43.16,33.03,53.72,"","table 1",TRUE,"N","IgG","CMIA","indirect",77,65,42,82,67.540319489751,68.3928769142377,45.8135356340701,84.3122482456997
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Abbott Architect IgG","n-290",22,89,24.72,16.19,35,"","table 1",TRUE,"N","IgG","CMIA","indirect",77,49,21,73,54.2277899953432,54.6605087326906,25.695931619127,80.2512633224413
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Abbott Architect IgG","n-290",18,91,19.78,12.16,29.45,"","table 1",TRUE,"N","IgG","CMIA","indirect",77,37,10,70,41.2899192604878,40.2336966190979,12.1703215274514,75.5597250876889
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Abbott Architect IgG","n-290",5,35,14.29,4.806,30.26,"","table 1",TRUE,"N","IgG","CMIA","indirect",77,10,1,26,30.3373007224927,27.3209578972376,5.27019399106668,70.343070001797
"3","South Asia","India","National","representative","--","--","12/27/2020",1,"Abbott Architect IgG","n-96",19,38,50,33.38,66.62,"Yes","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect",76,26,19,32,68.6997515067309,68.9694345579979,57.3845151987256,78.4674060502066
"--","Europe","Ireland","{ Dublin }","hospitalized + non-hospitalized patients","3/26/2020","7/10/2020","5/18/2020",1,"Abbott Architect IgG","n-225",149,185,80.54,74.09,85.98,"Yes","table 3",TRUE,"N","IgG","CMIA","indirect",76,158,93,180,82.2595976703282,85.3916543568555,50.7314289699515,97.0003009071602
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",1,"Abbott Architect IgG","n-240",40,42,95.24,83.84,99.42,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect",76,39,34,42,92.2339560272687,92.5218071848489,87.0414183512576,95.9597826539388
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Abbott Architect IgG","n-132",158,173,91.4,86.4,94.9,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect",76,140,124,153,80.5262553832513,80.7067225163399,73.9490277757054,86.0389464877405
"--","South Asia","India","{ Delhi }","hospitalized + non-hospitalized patients","--","--","12/18/2020",2,"Abbott Architect IgG","n-162",527,673,78.31,75,81.36,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect",76,545,294,646,77.8562657211114,80.9163549723062,43.6884210780928,95.7253882636205
"--","Oceania","Australia","{ Sydney }","hospitalized + non-hospitalized patients","*March 2020","*August 2020","--",2,"Abbott Architect IgG","n-215",116,166,69.88,62.29,76.75,"Yes","table 2",TRUE,"N","IgG","CMIA","indirect",76,134,71,160,77.6331021762163,80.5056465268933,43.3990942457208,95.8246714318941
"1","Europe","Italy","Vo'","representative","5/1/2020","5/3/2020","5/2/2020",2,"Abbott Architect IgG","n-108",60,62,96.77,88.83,99.61,"Yes","supplementary table 2",TRUE,"N","IgG","CMIA","indirect",76,50,26,60,77.7821726762253,80.6927920157335,44.2659837119666,95.778795054152
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",2,"Abbott Architect IgG","n-240",36,39,92.31,79.13,98.38,"Yes","table 1",TRUE,"N","IgG","CMIA","indirect",76,35,30,38,89.6155089316173,89.9152814031044,83.2273245576596,94.3608393663752
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Abbott Architect IgG","n-132",127,163,77.7,70.7,83.7,"Not yet","supplementary table 8",TRUE,"N","IgG","CMIA","indirect",76,112,95,127,68.4852159497433,68.5727504799596,61.7419794975287,74.7041235574946
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Abbott Architect IgG","n-134",29,41,70.73,54.46,83.87,"Yes","figure 1",TRUE,"N","IgG","CMIA","indirect",76,31,14,40,72.5391893403778,75.4116393943435,36.743112527788,94.1049180196713
"3","South Asia","India","National","representative","--","--","12/27/2020",3,"Abbott Architect IgG","n-96",51,96,53.12,42.66,63.39,"Yes","supplementary table (page 8 of appendix)",TRUE,"N","IgG","CMIA","indirect",76,52,37,65,53.6315892382739,53.7320899467919,42.5339299634506,64.2972253430988
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Abbott Architect IgG","n-290",33,39,84.62,69.47,94.14,"","table 1",TRUE,"N","IgG","CMIA","indirect",76,35,30,38,88.4127116254494,88.6642336512409,82.7874810705311,92.7625247923239
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",1.5,"Abbott Architect IgG","n-89",22,24,91.67,73,98.97,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect",76,21,15,24,84.9032233836205,85.792544299778,70.7131560181568,94.4392334715218
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Abbott Architect IgG","n-290",186,194,95.88,92.04,98.2,"","table 1",TRUE,"N","IgG","CMIA","indirect",76,165,149,178,84.7310478669775,84.9560263642787,78.5873717751145,89.7103827333733
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",2.5,"Abbott Architect IgG","n-89",26,29,89.66,72.65,97.81,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect",76,24,17,28,80.4389262756633,81.3993638439853,63.7827936979551,92.3375110392697
"1,2","South Asia","India","Tamil Nadu: Chennai","representative","7/17/2020","10/15/2020","8/31/2020",3.5,"Abbott Architect IgG","n-89",16,22,72.73,49.78,89.27,"","appendix table 8 (not yet included in seroreversion paper)",TRUE,"N","IgG","CMIA","indirect",76,17,10,21,75.0605625160098,75.9619258850164,56.1912225530569,89.6505199684756
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Abbott Architect IgG","n-290",106,123,86.18,78.8,91.74,"","table 1",TRUE,"N","IgG","CMIA","indirect",76,92,79,103,74.5171895705354,74.6547311100014,67.9648915219143,80.3342622370026
"1","Europe","Austria","Ischgl","representative","4/21/2020","4/27/2020","2020-04-24",1,"Abbott Architect IgG","n-109",99,105,94.29,87.98,97.87,NA,"table 2",FALSE,"N","IgG","CMIA","indirect",76,90,52,103,82.2284625543206,85.4088376698314,50.605974532156,96.8073502633089
"1","Europe","Spain","National","representative","4/27/2020","5/11/2020","2020-05-04",1,"Abbott Architect IgG","n-44",176,195,90.26,85.2,94.03,NA,"table 3",FALSE,"N","IgG","CMIA","indirect",76,166,99,190,82.38999366026,85.4389484438876,51.3427566699992,97.032298617431
"1","North America","USA","Davis, Salt Lake, Summit, and Utah counties","representative","5/1/2020","6/30/2020","2020-05-31",1,"Abbott Architect IgG","n-10",25,30,83.33,65.28,94.36,NA,"",FALSE,"N","IgG","CMIA","indirect",76,26,14.9750000000001,30,82.3770024752686,85.248529335751,51.8497970338019,96.9662579262177
"1","Africa","Ethiopia","14 towns (including Addis Ababa #2)","representative","6/24/2020","7/8/2020","2020-07-01",1,"Abbott Architect IgG","n-98",30,55,54.55,40.55,68.03,NA,"",FALSE,"N","IgG","CMIA","indirect",76,47,28,54,82.5036899550468,85.4403817097687,52.5347291814387,96.9205560631837
"2","South Asia","India","National","representative","8/17/2020","9/22/2020","2020-09-04",1,"Abbott Architect IgG","n-85",38,44,86.36,72.65,94.83,NA,"table 2 (excluded 3 samples for taken within 14 days)",FALSE,"N","IgG","CMIA","indirect",76,38,22,44,82.5878347639736,85.5667060508786,51.6343252725085,97.0045241969065
"1","South Asia","India","Kashmir: Srinagar district","representative","10/17/2020","10/20/2020","2020-10-18",1,"Abbott Architect IgG","n-92",100,121,82.64,74.7,88.92,NA,"table 1 (1 - 4 month time interval stated on page 1795)",FALSE,"N","IgG","CMIA","indirect",76,103,61,118,82.4008450381276,85.2946264403708,51.8811585086166,97.0484540187674
"1","South Asia","India","Kashmir (whole region)","representative","10/17/2020","11/4/2020","2020-10-26",2,"Abbott Architect IgG","n-91",140,172,81.4,74.76,86.91,NA,"176 individuals (with 4 seronegatives removed for testing earlier than 14 days)",FALSE,"N","IgG","CMIA","indirect",76,138,73,166,77.378216958354,80.3931677793647,42.4451068014889,95.688538751486
"4","South Asia","India","National","representative","6/14/2021","7/6/2021","2021-06-25",2,"Abbott Architect IgG","n-97",464,782,59.34,55.8,62.8,NA,"S1 table",FALSE,"N","IgG","CMIA","indirect",76,631,341,749,77.6927421966925,80.6608605785631,43.8115748006923,95.5837059286856
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",4.5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",11,11,100,71.51,100,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,11,9,11,97.4123420997131,97.7249441942551,93.823854568042,99.278835265807
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-222",338,363,93.11,90,95.49,"Yes","supplementary table S2",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,348,288,362,94.3460373903651,95.9630215563125,79.5835079210398,99.3341244357286
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",144,158,90.7,85.4,94.6,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,151,140,156,94.917436229725,95.227245331811,90.1153526443899,97.9108036629772
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",43,44,97.73,87.98,99.94,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,43,40,44,98.079005541626,98.4269701932327,94.5354729527568,99.6126354871676
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-167",367,376,97.61,95.5,98.9,"Yes","",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,364,304,375,95.2434263162149,96.8532767220797,80.8640549081325,99.5411716704176
"--","Europe","Germany","{ Saarland }","non-hospitalized patients","--","*October 2020","*October 2020",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-289",30,30,100,88.43,100,"Yes","figure 2g",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,29,24,30,95.3565867545384,96.8550724598249,82.0977892611564,99.5484393331668
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",133,146,91.1,85.7,95.1,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,142,131,146,96.5245879235198,97.0654314848164,90.8339645767912,99.1811937435694
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-165",53,58,91.38,81.02,97.14,"Yes","",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,57,49,58,96.7008565427698,98.0931721185759,85.3261190600739,99.7857959890526
"--","Europe","Sweden","{ Stockholm }","hospitalized + non-hospitalized patients","--","late 2020","--",9,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-223",31,32,96.88,83.78,99.92,"Yes","tables 2 and 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,32,27,32,97.1352150296798,98.4620361057911,86.217559544236,99.8615180765767
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",160,162,98.77,95.61,99.85,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,160,156,162,98.7592380843488,98.9038609247326,97.072289238329,99.6341120679715
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",93,95,97.89,92.6,99.74,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,95,91,95,99.146317178533,99.33538758545,97.374144954137,99.8541857132723
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",86,89,96.63,90.46,99.3,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,89,86,89,99.382492466311,99.5965090006738,97.5742568588431,99.9426434750345
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",84,91,92.31,84.79,96.85,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,91,88,91,99.5307051971454,99.7553972405222,97.7372049400538,99.9779917715753
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",34,35,97.14,85.08,99.93,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",75,35,34,35,99.6258977520198,99.8515069422362,97.8460453679829,99.9915485048368
"2.3","East Asia","Japan","Miyagi + Osaka + Tokyo (phase 3), Aichi + Fukuoka (phase 2)","representative","12/3/2021","12/27/2021","2021-12-15",5,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-280",105,132,79.55,71.65,86.07,NA,"table 4 on page 6",FALSE,"N","IgG IgM IgA","CMIA","sandwich",75,120,102,129,89.8899262465176,90.6833768785291,78.967385957325,96.330437322625
"1","South Asia","India","Odisha: Bhubaneswar (phase 2), Berhampur, Rourkela","representative","8/6/2020","8/31/2020","8/18/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-93",23,29,79.31,60.28,92.01,"Yes","table 2",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,28,21,29,93.3456738002552,95.2389546140103,75.7666118608507,99.1831270299416
"2","South Asia","India","Odisha: Bhubaneswar","representative","--","--","8/26/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-94",2,3,66.67,9.43,99.16,"Yes","table 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,3,2,3,93.4363772006767,95.1940288103373,77.8881837436772,99.1607567085553
"3","South Asia","India","Odisha: Bhubaneswar","representative","--","--","9/18/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-94",124,132,93.94,88.41,97.35,"Yes","table 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,126,100,132,93.4245699026724,95.2293696380961,76.7585341473219,99.1786967605287
"--","Europe","Ireland","{ Dublin }","hospitalized + non-hospitalized patients","3/26/2020","7/10/2020","5/18/2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-225",153,185,82.7,76.47,87.86,"Yes","table 3",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,176,141,184,93.4275516571827,95.2931312283376,76.6634005182408,99.1632844414566
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",147,164,89.6,84.2,93.7,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,153,139,160,92.6261420109974,93.0177683308073,86.3500962416041,96.5996090422464
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",39,42,92.86,80.52,98.5,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,41,37,42,96.9166332810472,97.3636417258624,91.8763694467974,99.3004008235384
"1","Europe","Italy","Vo'","representative","5/1/2020","5/3/2020","5/2/2020",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-108",62,62,100,94.22,100,"Yes","supplementary table 2",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,59,47,62,93.2894056780801,95.0904270443729,77.2814093762787,99.0662061706327
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-240",39,39,100,90.97,100,"Yes","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,38,35,39,96.8364927305578,97.2508474794698,92.0870482532666,99.2252029893317
"1","Europe","Iceland","National","convenience (general population)","4/3/2020","7/8/2020","5/21/2020",3,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-157",1120,1215,92.18,90.53,93.63,"Yes","tables S1 and S4, page 8 of appendix 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,1153,937,1204,93.1125672278901,94.8543600074108,77.1246744563749,99.0017513613039
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-134",40,41,97.56,87.14,99.94,"Yes","",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,39,30,41,93.0086682993487,94.7846485442644,76.5142498974288,99.05158181376
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-132",150,166,90.2,85,94.2,"Not yet","supplementary table 8",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,154,142,161,92.2185315686628,92.4288102557177,87.7117699214371,95.5140755407376
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",32,39,82.05,66.47,92.46,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,38,35,39,97.2892395298116,97.6147384139365,93.3627464684098,99.2538125470157
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",193,194,99.48,97.16,99.99,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,189,180,194,97.2509414455654,97.5180493148892,93.7886697067425,99.1202318538872
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-290",123,123,100,97.05,100,"","table 1",TRUE,"N","IgG IgM IgA","CMIA","sandwich",74,120,114,123,97.1403849670224,97.3037524352711,94.4571316820944,98.8081870910071
"1","South Asia","India","Puducherry: Puducherry district","representative","8/11/2020","8/16/2020","2020-08-13",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-87",3,3,100,29.24,100,NA,"",FALSE,"N","IgG IgM IgA","CMIA","sandwich",74,3,2,3,93.4201912225964,95.2180644122826,76.4058207642054,99.1842972655581
"2","South Asia","India","Puducherry: Puducherry district","representative","9/10/2020","9/16/2020","2020-09-13",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-87",3,7,42.86,9.899,81.59,NA,"",FALSE,"N","IgG IgM IgA","CMIA","sandwich",74,7,5,7,93.4835696222776,95.3347600219827,77.146199685277,99.1958744902535
"3","South Asia","India","Puducherry: Puducherry district","representative","10/12/2020","10/16/2020","2020-10-14",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-87",25,29,86.21,68.34,96.11,NA,"",FALSE,"N","IgG IgM IgA","CMIA","sandwich",74,28,21,29,93.4326627008398,95.2515052304977,76.8541116096416,99.2025753170967
"1","Oceania","Indonesia","Tanjung Priok sub-district","convenience (general population)","11/23/2020","2/19/2021","2021-01-06",2,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-152",27,32,84.38,67.21,94.72,NA,"table 2 (excluded 17 samples for taken within 14 days)",FALSE,"N","IgG IgM IgA","CMIA","sandwich",74,31,24,32,93.3188677141173,95.0482935458205,77.4356088071398,99.1304421339381
"1","South Asia","India","Hyderabad","representative","1/8/2021","1/24/2021","2021-01-16",4,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-101",260,298,87.25,82.92,90.82,NA,"table 2",FALSE,"N","IgG IgM IgA","CMIA","sandwich",74,282,226,296,92.9177813730998,94.7483789340421,76.0919988934546,99.0017415239455
"3.4","East Asia","Japan","Miyagi + Osaka + Tokyo (phase 4), Aichi + Fukuoka (phase 3)","representative","2/2/2022","3/6/2022","2022-02-18",1,"Elecsys Anti-SARS-CoV-2 Roche nucleocapsid IgG IgM","n-280",178,230,77.39,71.43,82.63,NA,"table 4 on page 6",FALSE,"N","IgG IgM IgA","CMIA","sandwich",74,193,165,212,83.4033061497967,83.8726317055442,72.8436432199827,91.2039463760457
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*August 2020","*October 2020","*September 2020",5,"Euroimmun anti-spike","n-133",90,109,82.57,74.13,89.17,"Yes","table 2",TRUE,"S","IgG IgA","ELISA","indirect",73,86,42,105,76.0302994090495,79.1726551302101,39.6609788255127,95.6481003224142
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Euroimmun anti-spike","n-222",280,363,77.13,72.46,81.36,"Yes","supplementary table S2",TRUE,"S","IgG IgA","ELISA","indirect",73,288,139,349,75.9153542608711,79.3230486563957,38.6264760351606,95.7489030023283
"--","Europe","Germany","{ Saarland }","non-hospitalized patients","--","*October 2020","*October 2020",6,"Euroimmun anti-spike","n-289",23,30,76.67,57.72,90.07,"Yes","figure 2g",TRUE,"S","IgG IgA","ELISA","indirect",73,23,9,29,72.8557224360227,76.0293306867761,33.7919248327511,95.486695101109
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","--","--","--",7,"Euroimmun anti-spike","n-243",103,131,78.63,70.61,85.3,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect",73,101,78,117,76.2704511030909,76.912535168727,61.3677203563748,87.7345831248145
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"Euroimmun anti-spike","n-165",40,58,68.97,55.46,80.46,"Yes","",TRUE,"S","IgG IgA","ELISA","indirect",73,41,14,56,66.9356863394609,70.1435275377011,24.7642497988136,94.3690842009776
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","--","12/17/2020","--",9,"Euroimmun anti-spike","n-243",96,131,73.28,64.85,80.63,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect",73,93,58,116,69.6148739321096,70.6852378714705,45.8506425719679,87.6198842964739
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*January 2021","*March 2021","*February 2021",10,"Euroimmun anti-spike","n-133",85,109,77.98,69.03,85.35,"Yes","table 2",TRUE,"S","IgG IgA","ELISA","indirect",73,69,16,103,60.4834735629529,63.1617206050064,15.5458588796741,93.4719046738176
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Euroimmun anti-spike","n-290",131,162,80.86,73.95,86.61,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",73,134,113,149,82.0608727477291,82.5793655122069,71.508918107571,90.0885392383881
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Euroimmun anti-spike","n-290",75,95,78.95,69.38,86.64,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",73,74,52,87,76.3675144152948,77.4536020054079,57.0240611219523,89.9807751810454
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Euroimmun anti-spike","n-290",71,89,79.78,69.93,87.55,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",73,64,35,82,69.7152232652532,71.44856670824,41.2676474158989,89.9145703680343
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Euroimmun anti-spike","n-290",66,91,72.53,62.17,81.37,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",73,59,23,83,62.5982005941724,64.4285128585253,26.790834721649,90.0761985846693
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Euroimmun anti-spike","n-290",27,35,77.14,59.86,89.58,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",73,20,5,32,55.5524421114791,56.8013065720525,15.9868422560934,90.1944823886728
"1","Europe","Germany","Freiburg + Breisgau-Hochschwarzwald","representative","8/5/2020","9/1/2020","2020-08-18",5,"Euroimmun anti-spike","n-26",12,16,75,47.62,92.73,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect",73,12,8,16,76.6747109021424,77.3423452910157,60.6830847251664,88.9020670524229
"1","Europe","Germany","Straubing","representative","9/8/2020","9/26/2020","2020-09-17",5,"Euroimmun anti-spike","n-295 , n-234",17,32,53.12,34.74,70.91,NA,"n-295 (tabelle 3 on page 25)",FALSE,"S","IgG IgA","ELISA","indirect",73,25,11,32,75.6916529533575,78.9086314405184,38.596808006313,95.6820879590427
"1","Europe","Germany","Aachen","representative","9/9/2020","10/9/2020","2020-09-24",6,"Euroimmun anti-spike","n-26",9,14,64.29,35.14,87.24,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect",73,10,6,14,73.5623068319077,74.4906209991046,53.5883919323742,88.3311761491561
"2","Europe","Germany","Reutlingen district","representative","10/14/2020","11/10/2020","2020-10-27",6,"Euroimmun anti-spike","n-26 , n-173",17,21,80.95,58.09,94.55,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect",73,16,6,21,73.0328871239368,76.2687211038011,34.5001130337363,95.1971402057364
"1.2","Europe","Germany","Chemnitz, unvaccinated population","representative","3/3/2021","8/17/2021","2021-05-25",5,"Euroimmun anti-spike","n-173",220,257,85.6,80.71,89.66,NA,"eSupplement-Table 3",FALSE,"S","IgG IgA","ELISA","indirect",73,197,161,225,76.2796986813658,76.7131496336454,63.7850809140892,86.2992039400231
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",1,"Euroimmun anti-spike","n-170",53,54,98.15,90.11,99.95,"","table 1 (not yet included in seroreversion paper)",TRUE,"S","IgG IgA","ELISA","indirect",72,45,26,53,80.3324185714683,82.9687913671494,50.1430793646597,96.0931301389598
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",2,"Euroimmun anti-spike","n-170",104,104,100,96.52,100,"Yes","table 1",TRUE,"S","IgG IgA","ELISA","indirect",72,85,49,101,79.3835944760745,82.0611314193091,48.3190446201172,95.8266512765849
"--","Europe","Netherlands","{ ? }","convenience (general population)","4/14/2020","--","--",2,"Euroimmun anti-spike","n-226",83,85,97.65,91.76,99.71,"Yes","",TRUE,"S","IgG IgA","ELISA","indirect",72,70,39,82,79.3027014180607,82.0260901411026,47.6777317976579,95.783771170522
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","4/6/2020","--","--",2,"Euroimmun anti-spike","n-243",113,131,86.26,79.16,91.65,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect",72,108,94,119,82.1275623622223,82.4257088682989,74.3202927153181,88.2610140384226
"--","Oceania","Australia","{ Sydney }","hospitalized + non-hospitalized patients","*March 2020","*August 2020","--",2,"Euroimmun anti-spike","n-215",121,166,72.89,65.46,79.49,"Yes","table 2",TRUE,"S","IgG IgA","ELISA","indirect",72,137,78,160,79.442167903863,82.2760537787407,48.3074413235629,95.7242021495973
"1","Europe","Germany","National (SOEP)","representative","--","--","11/11/2020",2,"Euroimmun anti-spike","n-68 , n-70",82,133,61.65,52.83,69.95,"Yes","pages 8 and 9",TRUE,"S","IgG IgA","ELISA","indirect",72,109,65,128,79.6119595591742,82.1711269596065,49.9875564848093,95.6974260411614
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","--","--","--",4,"Euroimmun anti-spike","n-243",113,131,86.26,79.16,91.65,"Yes","figure 5c, seropositives back-calculated from seroprevalence",TRUE,"S","IgG IgA","ELISA","indirect",72,105,93,116,80.2713397308599,80.4549742236191,73.7664297975343,85.7205896901207
"--","Europe","Netherlands","{ ? }","convenience (general population)","--","8/15/2020","--",4,"Euroimmun anti-spike","n-226",73,85,85.88,76.64,92.49,"Yes","",TRUE,"S","IgG IgA","ELISA","indirect",72,68,37,82,77.5620483664114,80.449337059135,45.228433437767,95.0543651551061
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Euroimmun anti-spike","n-290",33,39,84.62,69.47,94.14,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",72,34,28,38,85.5632752197659,85.8544020619927,77.792038739575,91.4498028647167
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Euroimmun anti-spike","n-290",176,194,90.72,85.73,94.41,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",72,165,147,179,84.8263170261691,85.0592329601501,77.665330558346,90.4528795150003
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Euroimmun anti-spike","n-290",108,123,87.8,80.68,93.01,"","table 1",TRUE,"S","IgG IgA","ELISA","indirect",72,103,91,112,83.2223987778313,83.3735165448778,77.3347046881055,88.1827044611665
"1","Europe","Austria","Ischgl","representative","4/21/2020","4/27/2020","2020-04-24",1,"Euroimmun anti-spike","n-109",98,105,93.33,86.75,97.28,NA,"table 2",FALSE,"S","IgG IgA","ELISA","indirect",72,87,51,102,80.4101444382171,83.1114067961043,50.1382146669108,96.0596082147961
"1","Europe","France","National","representative","--","--","2020-05-21",3,"Euroimmun anti-spike","n-149",74,83,89.16,80.41,94.92,NA,"table 2",FALSE,"S","IgG IgA","ELISA","indirect",72,67,38,80,78.4101725112113,80.8778825894468,47.3639612859754,95.3713168374862
"1","Europe","France","Grand Est, Île-de-France, Nouvelle-Aquitaine","representative","5/4/2020","6/23/2020","2020-05-29",1,"Euroimmun anti-spike","n-31",68,78,87.18,77.68,93.68,NA,"table 2",FALSE,"S","IgG IgA","ELISA","indirect",72,65,38,76,80.4120494369556,82.9927024509121,51.2808963753312,96.0581208823259
"1","Europe","Germany","Kupferzell","representative","5/20/2020","6/9/2020","2020-05-30",2,"Euroimmun anti-spike","n-110 , n-295",43,50,86,73.26,94.18,NA,"table 3",FALSE,"S","IgG IgA","ELISA","indirect",72,41,23,49,79.4550405479131,82.060383646458,48.8120267616604,95.6508759736096
"1","Europe","Germany","Bad Feilnbach","representative","6/23/2020","7/4/2020","2020-06-28",3,"Euroimmun anti-spike","n-295",22,42,52.38,36.42,68,NA,"n-295 (tabelle 3 on page 25)",FALSE,"S","IgG IgA","ELISA","indirect",72,34,19,41,78.4918280662535,80.9715088910553,47.5434568877283,95.3940376993232
"1","South Asia","India","Pune (five prabhags/subwards)","representative","7/20/2020","8/5/2020","2020-07-28",1,"Euroimmun anti-spike","n-84",19,21,90.48,69.62,98.83,NA,"tables 1 and 2",FALSE,"S","IgG IgA","ELISA","indirect",72,17,9,21,80.3414202419819,82.919072569747,50.0531328666394,95.9465774816564
"1","Europe","Germany","Reutlingen district","representative","7/1/2020","7/28/2020","2020-07-14",3,"Euroimmun anti-spike","n-26",10,11,90.91,58.72,99.77,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect",72,8,5,11,75.0000734900861,75.4809796436046,60.7095047603598,86.5539645212722
"1","Europe","Germany","Osnabrück district + Osnabrück city","representative","10/15/2020","11/15/2020","2020-10-30",3,"Euroimmun anti-spike","n-26",11,17,64.71,38.33,85.79,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect",72,13,8,16,75.0000734900861,75.4809796436046,60.7095047603598,86.5539645212722
"1","Europe","Germany","Mitte (in Berlin)","representative","11/17/2020","12/5/2020","2020-11-26",1,"Euroimmun anti-spike","n-295 , n-236",21,35,60,42.11,76.13,NA,"n-295 (tabelle 3 on page 25)",FALSE,"S","IgG IgA","ELISA","indirect",72,29,16,35,80.3370194833658,82.9806312810158,49.607423040329,96.1499193168607
"2","Europe","Germany","Freiburg + Breisgau-Hochschwarzwald","representative","11/18/2020","12/15/2020","2020-12-01",2,"Euroimmun anti-spike","n-26 , n-173",10,11,90.91,58.72,99.77,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect",72,9,4,11,79.3971942602552,82.1396656054664,47.7788894278605,95.7445138025144
"1","Europe","Germany","Magdeburg","representative","11/18/2020","12/15/2020","2020-12-01",1,"Euroimmun anti-spike","n-26",26,28,92.86,76.5,99.12,NA,"page 20",FALSE,"S","IgG IgA","ELISA","indirect",72,22,15,26,77.2226923434037,77.7619938221148,62.6918888187386,88.4259060264031
"2","Europe","Germany","Aachen region, unvaccinated population","representative","1/25/2021","2/27/2021","2021-02-10",3,"Euroimmun anti-spike","n-26 , n-173",61,70,87.14,76.99,93.95,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect",72,57,32,68,78.3845030702927,80.8539674805799,47.2043686773365,95.3097436503275
"2","Europe","Germany","Osnabrück district + Osnabrück city, unvaccinated population","representative","3/1/2021","3/31/2021","2021-03-16",3,"Euroimmun anti-spike","n-26 , n-173",34,37,91.89,78.09,98.3,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect",72,30,16,36,78.6299261533005,81.2506857362989,47.6457557342027,95.5261418448272
"2","Europe","Germany","Magdeburg, unvaccinated population","representative","4/7/2021","5/5/2021","2021-04-21",3,"Euroimmun anti-spike","n-26 , n-173",33,40,82.5,67.22,92.66,NA,"n-26 (page 20), n-173 (eSupplement-Table 3)",FALSE,"S","IgG IgA","ELISA","indirect",72,33,18,39,78.6178636771675,81.1786648420688,47.6411865723553,95.491461023324
"1","Europe","Germany","Vorpommern-Greifswald, unvaccinated population","representative","5/12/2021","6/8/2021","2021-05-25",3,"Euroimmun anti-spike","n-173",70,86,81.4,71.55,88.98,NA,"eSupplement-Table 3",FALSE,"S","IgG IgA","ELISA","indirect",72,75,67,81,86.8053940488484,86.9410069843171,82.3231185004331,90.6246888639909
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",6,"Diasorin Liaison S1/S2 spike IgG","n-240",39,44,88.64,75.44,96.21,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect",71,39,31,43,87.0304850550437,87.6536648402676,76.0681953487217,94.3250452539707
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Diasorin Liaison S1/S2 spike IgG","n-132",49,71,68.7,57.2,79.1,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",71,54,43,63,75.3631544667055,75.6415931019078,64.6005747085924,84.3623931018044
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*January 2021","*March 2021","*February 2021",10,"Diasorin Liaison S1/S2 spike IgG","n-133",91,109,83.49,75.16,89.91,"Yes","table 2",TRUE,"S","IgG","CMIA","indirect",71,80,59,96,73.1479019939296,73.8043348582086,56.2408183572946,86.4308986552612
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Diasorin Liaison S1/S2 spike IgG","n-290",137,162,84.57,78.07,89.76,"","table 1",TRUE,"S","IgG","CMIA","indirect",71,138,122,150,84.9467431107778,85.2178601650768,77.5108942511008,90.8126257960813
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Diasorin Liaison S1/S2 spike IgG","n-290",84,95,88.42,80.23,94.08,"","table 1",TRUE,"S","IgG","CMIA","indirect",71,79,64,89,82.3487066909689,82.9251355632351,70.2598901029284,91.0585740371791
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Diasorin Liaison S1/S2 spike IgG","n-290",78,89,87.64,78.96,93.67,"","table 1",TRUE,"S","IgG","CMIA","indirect",71,72,53,83,79.3478366180111,80.3340589636372,61.16167527318,91.5657215801665
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Diasorin Liaison S1/S2 spike IgG","n-290",72,91,79.12,69.33,86.94,"","table 1",TRUE,"S","IgG","CMIA","indirect",71,71,45,85,75.9935527848492,77.536109918009,51.1090444932144,92.0212252776195
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Diasorin Liaison S1/S2 spike IgG","n-290",30,35,85.71,69.74,95.19,"","table 1",TRUE,"S","IgG","CMIA","indirect",71,26,13,33,72.3752669295733,74.443856942353,41.0659372614909,92.5301393579972
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Diasorin Liaison S1/S2 spike IgG","n-132",121,140,86.5,80,91.5,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",70,106,83,123,75.1648915818794,75.6713350698409,61.4509908374958,86.2742855578792
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",1,"Diasorin Liaison S1/S2 spike IgG","n-240",37,42,88.1,74.37,96.02,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect",70,38,31,42,89.5514448614373,90.159438135387,79.5903268128379,96.0378804772726
"--","Oceania","Australia","{ Sydney }","hospitalized + non-hospitalized patients","*March 2020","*August 2020","--",2,"Diasorin Liaison S1/S2 spike IgG","n-215",134,166,80.72,73.89,86.43,"Yes","table 2",TRUE,"S","IgG","CMIA","indirect",70,144,86,163,83.8337842039833,86.9815852627617,52.4382220249095,97.620491495468
"1","Europe","Italy","Vo'","representative","5/1/2020","5/3/2020","5/2/2020",2,"Diasorin Liaison S1/S2 spike IgG","n-108",53,62,85.48,74.22,93.14,"Yes","supplementary table 2",TRUE,"S","IgG","CMIA","indirect",70,54,31,61,83.6642396026234,86.8710758037534,51.4364754254119,97.6290191524751
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",2,"Diasorin Liaison S1/S2 spike IgG","n-240",36,39,92.31,79.13,98.38,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect",70,35,29,39,89.2289689194868,89.7825932647418,79.6298947621349,95.7243441559254
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Diasorin Liaison S1/S2 spike IgG","n-134",38,41,92.68,80.08,98.46,"Yes","",TRUE,"S","IgG","CMIA","indirect",70,35,20,41,83.2657109582243,86.5444720120856,51.8484120759065,97.5135557641933
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Diasorin Liaison S1/S2 spike IgG","n-132",135,166,81.6,75,87,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",70,123,100,142,73.7948426247063,74.1012953362709,61.8389075250474,83.8984275470312
"--","Oceania","Australia","{ Victoria }","hospitalized + non-hospitalized patients","--","--","--",4.5,"Diasorin Liaison S1/S2 spike IgG","n-240",11,11,100,71.51,100,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect",70,10,7,11,88.3228660724576,88.8074193669628,78.9620863158535,95.0386914827199
"--","Europe","Germany","Dresden","hospitalized + non-hospitalized patients","*August 2020","*October 2020","*September 2020",5,"Diasorin Liaison S1/S2 spike IgG","n-133",88,109,80.73,72.07,87.66,"Yes","table 2",TRUE,"S","IgG","CMIA","indirect",70,94,81,103,85.8434976935676,86.2266825622406,77.2028752343589,92.2227762543967
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Diasorin Liaison S1/S2 spike IgG","n-222",295,363,81.27,76.87,85.15,"Yes","supplementary table S2",TRUE,"S","IgG","CMIA","indirect",70,311,178,354,82.3891739732748,85.6082957681481,49.4230803506632,97.3356145936924
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Diasorin Liaison S1/S2 spike IgG","n-132",94,125,75.7,67.5,82.8,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",70,91,73,105,72.301283224396,72.4786025311878,61.4973070621369,81.8296665839133
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Diasorin Liaison S1/S2 spike IgG","n-290",31,39,79.49,63.54,90.7,"","table 1",TRUE,"S","IgG","CMIA","indirect",70,35,29,38,88.2303664548316,88.7002767612037,79.5919544223115,94.1527864286402
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Diasorin Liaison S1/S2 spike IgG","n-290",172,194,88.66,83.34,92.76,"","table 1",TRUE,"S","IgG","CMIA","indirect",70,171,153,184,87.9098742270558,88.2834694819855,80.1740716668748,93.4804978788945
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Diasorin Liaison S1/S2 spike IgG","n-290",112,123,91.06,84.56,95.45,"","table 1",TRUE,"S","IgG","CMIA","indirect",70,108,96,116,87.1996331938631,87.42726274942,81.2054040971433,91.9723449170641
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Vitros Ortho total Ig anti-spike","n-132",158,162,97.8,94.7,99.3,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",69,156,148,161,95.8188336956117,95.9952096696127,92.6769070174486,98.000530461706
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Vitros Ortho total Ig anti-spike","n-290",90,95,94.74,88.14,98.27,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",69,94,92,95,98.9977230703638,99.068972684985,97.9864507167235,99.6087327516125
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Vitros Ortho total Ig anti-spike","n-290",86,89,96.63,90.46,99.3,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",69,89,87,89,99.4977742490852,99.5599018020603,98.7825445281502,99.8588641351536
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Vitros Ortho total Ig anti-spike","n-290",88,91,96.7,90.67,99.31,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",69,91,89,91,99.7443988287431,99.7920161244202,99.2584028702836,99.9499443515224
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Vitros Ortho total Ig anti-spike","n-290",35,35,100,90,100,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",69,35,34,35,99.8677494131159,99.9017829460841,99.5438955208436,99.9821338268943
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Vitros Ortho total Ig anti-spike","n-132",86,126,68.5,60,76.5,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,119,103,125,93.4551285947848,94.3947369643531,83.4184872839703,98.400198385987
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Vitros Ortho total Ig anti-spike","n-132",132,157,83.9,77.5,89.2,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,150,138,156,95.1293005774052,95.6035119879072,89.0436788804947,98.4698559110519
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Vitros Ortho total Ig anti-spike","n-132",139,149,93.4,88.6,96.7,"Not yet","supplementary table 8",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,144,136,148,96.3199065781432,96.5638377133419,92.5090201428407,98.6689461626803
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Vitros Ortho total Ig anti-spike","n-290",33,39,84.62,69.47,94.14,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,35,25,39,87.8431912073835,89.8267422834596,66.8972858801809,97.6214576551292
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Vitros Ortho total Ig anti-spike","n-290",180,194,92.78,88.19,96,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,177,140,191,89.4723883255626,91.0015732487049,72.9247899214338,97.5918882275467
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Vitros Ortho total Ig anti-spike","n-290",118,123,95.93,90.77,98.67,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,114,99,121,92.1468275065928,92.918284615188,82.3304622713728,97.5411125157945
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Vitros Ortho total Ig anti-spike","n-290",158,162,97.53,93.8,99.32,"","table 1",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",68,153,141,160,94.1188596826472,94.4642337309797,88.7382264340359,97.542359124188
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",160,162,98.77,95.61,99.85,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",67,160,153,162,98.2754619554237,98.5085368686226,95.6375830599844,99.5626837673821
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",95,95,100,96.19,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",67,94,89,95,98.420247420734,98.8472260370185,94.5421577656558,99.7896776756422
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",88,89,98.88,93.9,99.97,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",67,88,82,89,98.4506182421421,99.1074814620972,92.9869428671737,99.9044480316111
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",91,91,100,96.03,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",67,90,82,91,98.3866304116233,99.3099011541589,90.8553411193051,99.9565760392403
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",35,35,100,90,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",67,35,30,35,98.2410465631337,99.4672789714163,88.1313688523694,99.9802340670503
"1","Europe","Italy","Caldari Ortona (Villa Caldari)","representative","4/18/2020","4/19/2020","4/18/2020",1,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-107",7,7,100,59.04,100,"Yes","",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,7,4,7,91.3630329102838,93.9759453985164,67.9720202336736,99.2162101219749
"1 - 4","Europe","Denmark","National (SSI) + 30 municipalities subset","representative","5/18/2020","12/16/2020","9/1/2020",2,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-22",217,232,93.53,89.56,96.34,"Yes","page 719",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,221,172,231,93.1991646778041,95.3819897573395,74.727690622695,99.3604161012102
"1","Europe","Iceland","{ National }","convenience (general population)","4/3/2020","7/8/2020","5/21/2020",3,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-157",1143,1215,94.07,92.6,95.33,"Yes","tables S1 and S4, page 8 of appendix 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,1172,958,1210,94.6071703809407,96.4347790529799,79.0230612230623,99.4806283903774
"5","Europe","Denmark","National (SSI), unvaccinated population","representative","2/27/2021","4/20/2021","*3/17/2021",4,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-194",484,514,94.16,91.77,96.03,"Yes","page 4",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,500,425,513,95.7146055120866,97.2232991372181,83.117179613326,99.6269725057303
"6","Europe","Denmark","National (SSI), unvaccinated population","representative","5/14/2021","7/11/2021","*6/10/2021",5,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-195",282,310,90.97,87.21,93.91,"Yes","page 4",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,303,264,310,96.5703105747858,97.830015331649,85.4968411517386,99.7416320638958
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",36,39,92.31,79.13,98.38,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,37,31,39,94.7047840472546,95.8487279582634,83.8685317624454,99.1133769178309
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",190,194,97.94,94.81,99.44,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,188,171,193,96.0823435241805,96.7766568725813,89.1877961013216,99.1971674257292
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Wantai ELISA SARS-CoV-2 Total Antibody, IgG IgM anti-RBD","n-290",123,123,100,97.05,100,"","table 1",TRUE,"RBD","IgG IgM","ELISA","sandwich",66,121,115,123,97.8222837720531,98.0637130154359,94.9877768452494,99.3868819442683
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"GenScript cPass neutralization kit","n-290",90,95,94.74,88.14,98.27,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",65,80,68,89,84.1554975586554,84.6064104404141,74.0538442595034,91.5691467811575
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"GenScript cPass neutralization kit","n-290",86,89,96.63,90.46,99.3,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",65,72,54,83,79.8494661934024,80.8732178552918,62.5380464615624,91.6195100815501
"--","Oceania","New Zealand","{ Southern District Health Board region }","hospitalized + non-hospitalized patients","3/11/2020","4/5/2020","--",10,"GenScript cPass neutralization kit","n-198",35,37,94.59,81.81,99.34,"Yes","",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",65,31,12,37,78.8553821132095,83.635442616773,35.9413718468194,97.8048743927161
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"GenScript cPass neutralization kit","n-290",82,91,90.11,82.05,95.38,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",65,70,43,85,74.7878492285488,76.4376492609575,48.999051788429,91.7954196159535
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"GenScript cPass neutralization kit","n-290",33,35,94.29,80.84,99.3,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",65,25,11,33,69.2057920160421,71.2632179935866,35.3967386481675,91.9447622444014
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"GenScript cPass neutralization kit","n-290",35,39,89.74,75.78,97.13,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",64,37,30,39,93.0368995088653,94.0915165512732,81.1496056169309,98.4909523961874
"--","Europe","Netherlands","{ ? }","convenience (general population)","4/14/2020","--","--",2,"GenScript cPass neutralization kit","n-226",85,85,100,95.75,100,"Yes","",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",64,79,55,85,89.8165410109034,92.5166922432942,65.476903696444,98.8947364270098
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"GenScript cPass neutralization kit","n-290",180,194,92.78,88.19,96,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",64,183,159,192,93.2208739175037,94.0921067779133,83.023756066604,98.2647743790435
"--","Europe","Netherlands","{ ? }","convenience (general population)","--","8/15/2020","--",4,"GenScript cPass neutralization kit","n-226",83,85,97.65,91.76,99.71,"Yes","",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",64,79,55,85,89.883747875157,92.5398023831837,66.0229994855307,98.7748624566856
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"GenScript cPass neutralization kit","n-290",114,123,92.68,86.56,96.6,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",64,116,104,122,93.5136839585071,94.0402042214965,86.1660303921393,97.7526639977613
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"GenScript cPass neutralization kit","n-290",139,162,85.8,79.46,90.78,"","table 1",TRUE,"RBD",NA,"NT (protein-protein ELISA)","competitive",64,152,141,159,93.7059731856122,93.9836061235961,88.5404844331137,97.1129786321503
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Euroimmun anti-nucleocapsid IgG IgM","n-290",49,95,51.58,41.1,61.96,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",63,52,36,66,54.4114655922449,54.416267218002,41.869475517512,66.6992751370636
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Euroimmun anti-nucleocapsid IgG IgM","n-290",31,89,34.83,25.04,45.67,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",63,34,18,53,38.4934517467077,38.0903915075926,22.8211478636479,56.3675807217192
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Euroimmun anti-nucleocapsid IgG IgM","n-290",23,91,25.27,16.75,35.47,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",63,22,8,43,25.1509393496019,24.077225675613,10.7314156981221,45.5081098615423
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Euroimmun anti-nucleocapsid IgG IgM","n-290",6,35,17.14,6.562,33.65,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",63,5,0,14,15.5876281978276,14.0727176340212,4.60966233915411,35.2639042601567
"--","Europe","Netherlands","{ ? }","convenience (general population)","4/14/2020","--","--",2,"Euroimmun anti-nucleocapsid IgG IgM","n-226",77,85,90.59,82.29,95.85,"Yes","",TRUE,"N","IgG IgM","ELISA","indirect",62,71,36,83,79.9427733896127,83.4745979339545,44.0275995777738,97.1675109827033
"--","Europe","Netherlands","{ ? }","convenience (general population)","--","8/15/2020","--",4,"Euroimmun anti-nucleocapsid IgG IgM","n-226",71,85,83.53,73.91,90.69,"Yes","",TRUE,"N","IgG IgM","ELISA","indirect",62,64,25,82,71.2269480908319,74.7639774886161,30.5807374256802,95.1605287101026
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Euroimmun anti-nucleocapsid IgG IgM","n-290",31,39,79.49,63.54,90.7,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",62,34,26,38,85.782224409646,86.7892439415834,71.3567128220208,94.6639770567657
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Euroimmun anti-nucleocapsid IgG IgM","n-290",180,194,92.78,88.19,96,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",62,162,129,181,82.5034866396093,83.3962209752857,67.8935048536545,92.3967168308097
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Euroimmun anti-nucleocapsid IgG IgM","n-290",105,123,85.37,77.86,91.09,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",62,92,71,107,74.0073950302733,74.5707645835165,60.0189754686933,85.239398752217
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Euroimmun anti-nucleocapsid IgG IgM","n-290",108,162,66.67,58.84,73.87,"","table 1",TRUE,"N","IgG IgM","ELISA","indirect",62,102,79,122,62.8690093354755,63.0408413716415,51.2601462202254,73.3455704312688
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",8,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",95,95,100,96.19,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",61,95,94,95,99.8349677737487,99.9099879521494,99.2044505429821,99.9959245098331
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",10,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",88,89,98.88,93.9,99.97,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",61,89,88,89,99.9080412403868,99.9677844606013,99.4252298610759,99.9994373625204
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",12,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",91,91,100,96.03,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",61,91,90,91,99.9432080219922,99.9884102317758,99.5701467703894,99.9999215549142
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",14,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",35,35,100,90,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",61,35,35,35,99.9615773251169,99.9958108947436,99.6806975873014,99.9999892305447
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",1,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",35,39,89.74,75.78,97.13,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",60,37,30,39,94.3463506693706,95.8823396166037,80.4222634491253,99.3383391657073
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",2,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",192,194,98.97,96.33,99.87,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",60,188,166,194,95.7930084209352,96.7999776234673,86.2234901005899,99.4128960744156
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",4,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",123,123,100,97.05,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",60,121,113,123,97.6493473179283,98.082642713178,93.1719350800665,99.5696999698201
"--","Europe","Germany","--","hospitalized + non-hospitalized patients","--","--","*2020",6,"Elecsys Anti-SARS-CoV-2 Roche spike","n-290",162,162,100,97.75,100,"","table 1",TRUE,"RBD","IgG IgM IgA","CMIA","sandwich",60,160,155,162,98.6402265844059,98.8422900862432,96.4047383241031,99.7381146458769
"1","South Asia","Maldives","greater Male’ area","representative","10/15/2020","11/16/2020","10/31/2020",4,"Vitros Ortho (not total) IgG anti-spike","n-151",77,133,57.89,49.03,66.4,"Yes","table 1",TRUE,"S","IgG","CMIA","indirect",59,104,46,129,74.9332622976863,78.4504287855761,35.7267069656603,96.0557161606599
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",5,"Vitros Ortho (not total) IgG anti-spike","n-132",111,147,75.1,67.8,82,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",59,113,86,132,76.3841880209731,77.0431610798647,60.1345705730682,88.4328973468178
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",7,"Vitros Ortho (not total) IgG anti-spike","n-132",72,113,63.5,54.4,72.4,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",59,75,38,101,65.2849687319716,66.5800174928735,35.0214833265142,87.9957912938926
"6","South Asia","India","Delhi, unvaccinated population","representative","9/24/2021","10/14/2021","2021-10-04",6,"Vitros Ortho (not total) IgG anti-spike","n-153",1739,2143,81.15,79.43,82.78,NA,"table 4",FALSE,"S","IgG","CMIA","indirect",59,1465,447,2033,65.1687593103471,68.4134260511488,20.958038428516,94.8649006256669
"--","North America","USA","{ San Francisco }","non-hospitalized patients","*April 2020","*July 2020","--",1,"Vitros Ortho (not total) IgG anti-spike","n-132",157,172,91,86.3,95,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",58,150,124,164,86.4201750077437,87.2099430240924,73.296797773391,94.6225291174736
"--","North America","USA","{ San Francisco }","non-hospitalized patients","--","--","--",3,"Vitros Ortho (not total) IgG anti-spike","n-132",139,165,84.3,78.5,89.8,"Not yet","supplementary table 8",TRUE,"S","IgG","CMIA","indirect",58,135,115,150,81.3193111807084,81.6612249145245,71.4246906742788,88.9715139974641
"1","North America","USA","Connecticut","representative","6/10/2020","7/29/2020","2020-07-04",2,"Vitros Ortho (not total) IgG anti-spike","n-2",11,11,100,71.51,100,NA,"table 3",FALSE,"S","IgG","CMIA","indirect",58,9,4,11,80.4013238521759,83.7889662545838,46.1813461142659,96.8605741010941
"5","South Asia","India","Delhi, unvaccinated population","representative","1/11/2021","1/22/2021","2021-01-16",3,"Vitros Ortho (not total) IgG anti-spike","n-86",817,1121,72.88,70.18,75.47,NA,"table 2",FALSE,"S","IgG","CMIA","indirect",58,904,476,1077.025,77.4594306667727,80.6029228071378,42.6312777505058,96.0113351978002
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",3,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",23,25,92,73.97,99.02,"Yes","",TRUE,"S","IgG","ELISA","indirect",57,24,19,25,92.6484502194874,93.5467968642467,81.8007772955381,98.2461648613543
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",4,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",26,26,100,86.77,100,"Yes","",TRUE,"S","IgG","ELISA","indirect",57,25,19,26,92.7812927212277,94.2184060654298,78.1182002753191,98.9477262148866
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",5,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",27,31,87.1,70.17,96.37,"Yes","",TRUE,"S","IgG","ELISA","indirect",57,30,22,31,92.6510792938368,94.8899930222774,72.937699223218,99.4121716147228
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",1,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",23,26,88.46,69.85,97.55,"Yes","",TRUE,"S","IgG","ELISA","indirect",56,24,20,26,92.3646031261529,93.2343148870288,81.7686791232824,97.8767210353806
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",1,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-170",54,54,100,93.4,100,"Yes","table 1 (not yet included in seroreversion paper)",TRUE,"S","IgG","ELISA","indirect",56,49,32,54,88.2016546400056,91.0551121980462,61.8717717456339,98.543012769415
"--","Latin America","Brazil","{ Rio de Janeiro city }","hospitalized + non-hospitalized patients","--","--","--",2,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-170",107,107,100,96.61,100,"Yes","table 1",TRUE,"S","IgG","ELISA","indirect",56,97,63,106,87.6728918155119,90.6315515006783,59.7940553942146,98.4407208321273
"--","Latin America","Brazil","{ Pelotas }","hospitalized + non-hospitalized patients","--","--","*November 2020",2,"University of Rio de Janeiro (UFRJ) anti-spike ELISA","n-171",24,26,92.31,74.87,99.05,"Yes","",TRUE,"S","IgG","ELISA","indirect",56,24,20,26,92.4668851442255,93.0257186053188,84.6207281318717,97.2176175121502
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",4,"Livzon COVID-19 IgG IgM lateral flow","n-105",9,41,21.95,10.56,37.61,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect",55,6,1,14,16.4209579712461,15.6520853576702,6.84836769022211,30.3239670362098
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",6,"Livzon COVID-19 IgG IgM lateral flow","n-105",51,261,19.54,14.91,24.88,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect",55,21,3,75,9.90946190516752,8.13338442223875,1.74281497645249,28.3938488125666
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",7,"Livzon COVID-19 IgG IgM lateral flow","n-105",8,41,19.51,8.821,34.87,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect",55,2,0,12,7.88384426780022,5.75714129812872,0.862599953239419,27.4862314232286
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",1,"Livzon COVID-19 IgG IgM lateral flow","n-105",77,216,35.65,29.27,42.43,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect",54,107,50,164,49.5624846496468,49.5880281057598,24.0647918247184,74.8788838833279
"1","Europe","Denmark","National (We test)","representative","10/2/2020","10/11/2020","10/6/2020",2,"Livzon COVID-19 IgG IgM lateral flow","n-105",51,188,27.13,20.91,34.08,"Yes","supplementary figure 7",TRUE,NA,"IgG IgM","LFIA","indirect",54,80,41,123,42.9309866860017,42.6359477669264,22.9541516342425,64.3302682526743
"1","Europe","Andorra","National","representative","5/4/2020","5/13/2020","2020-05-08",1,"Livzon COVID-19 IgG IgM lateral flow","n-43",305,378,80.69,76.34,84.55,NA,"",FALSE,NA,"IgG IgM","LFIA","indirect",54,285,107,362,71.7005160990938,75.4669065921318,28.46725636581,95.6167920565881
"3","South Asia","India","National","representative","--","--","12/27/2020",5,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",44,74,59.46,47.41,70.73,"Yes","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect",53,41,23,57,54.788186372909,54.9865963072028,33.9507033497856,74.5844157562552
"3","South Asia","India","National","representative","--","--","12/27/2020",7,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",12,23,52.17,30.59,73.18,"N","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect",53,11,3,19,47.5961511594135,47.4287451078711,17.2733648826264,79.3483774762841
"3","South Asia","India","National","representative","--","--","12/27/2020",1,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",25,38,65.79,48.65,80.37,"Yes","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect",52,30,19,37,77.9663613718642,79.7098630866236,54.1895268625618,92.7660673250422
"3","South Asia","India","National","representative","--","--","12/27/2020",3,"Siemens Advia SARS-CoV-2 IgG anti-RBD","n-96",60,96,62.5,52.03,72.18,"Yes","supplementary table (page 8)",TRUE,"RBD","IgG","CMIA","indirect",52,68,50,83,70.651110681056,71.2346106108964,54.6224277767261,83.6277317526702
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",41,44,93.18,81.34,98.57,"Yes","table 3",TRUE,"N, S","IgG IgM","LFIA","indirect",51,43,39,44,97.1649478048849,97.7022926871576,91.6098786441695,99.5161599862072
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",65,79,82.28,72.06,89.96,"Yes","table 3",TRUE,"N, S","IgG IgM","LFIA","indirect",51,78,67,79,96.9022923312621,98.2080149283084,85.8890434042377,99.8522535465523
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",30,32,93.75,79.19,99.23,"Yes","table 2",TRUE,"N, S","IgG IgM","LFIA","indirect",50,30,24,32,91.5251842833392,92.6194074189831,79.6250013601347,97.7632225597749
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Roche SARS-CoV-2 rapid antibody test anti-spike anti-nucleocapsid IgG IgM","n-213",151,154,98.05,94.41,99.6,"Yes","table 3",TRUE,"N, S","IgG IgM","LFIA","indirect",50,141,122,150,90.6560378040801,91.3997246957048,80.7362929894014,96.656196326064
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",42,43,97.67,87.71,99.94,"Yes","table 3",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA,49,42,38,43,96.8128643161611,97.3585605494139,91.0340524136988,99.4046885518701
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",56,57,98.25,90.61,99.96,"Yes","table 3",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA,49,56,48,57,96.6189039212867,97.9573952764619,84.8776015504167,99.8300733839037
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",52,56,92.86,82.71,98.02,"Yes","table 2",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA,48,54,46,56,94.7725965632996,95.7732927784848,84.6545492398682,99.0455810573639
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"LumiraDx SARS-CoV-2 anti-spike antibody test","n-213",150,153,98.04,94.38,99.59,"Yes","table 3",TRUE,"RBD, S","IgG IgM IgA","CMIA",NA,48,147,134,153,95.7144235144289,96.3222713107769,88.8512153878888,99.014284032206
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*October 2020",8,"in-house THL Finland neutralization assay","n-184",335,367,91.28,87.91,93.96,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,NA,NA,"NT (cell)",NA,47,344,223,365,90.423159339992,93.8286662938777,60.8098915086972,99.3247241822071
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*May 2021",13,"in-house THL Finland neutralization assay","n-184",320,367,87.19,83.34,90.44,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,NA,NA,"NT (cell)",NA,47,347,151,367,88.5176313001093,94.4840541949347,41.6929155388616,99.7652666813474
"--","Europe","Finland","{ Helsinki }","convenience (general population)","--","--","--",4,"in-house THL Finland neutralization assay","n-183",63,64,98.44,91.6,99.96,"Yes","",TRUE,NA,NA,"NT (cell)",NA,46,57,35,64,86.1849314880313,89.4562237491223,55.1996406565849,98.2910067210687
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","*early November 2020","December 2020","--",7,"in-house THL Finland neutralization assay","n-182",792,867,91.35,89.28,93.14,"N","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,NA,NA,"NT (cell)",NA,46,757,435,850,83.8444093652467,87.2977489120416,50.2746154836696,97.9142188286057
"2","Europe","England","National (REACT-2)","representative","7/31/2020","8/13/2020","2020-08-06",3,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-102",274,360,76.11,71.36,80.42,NA,"supplemental table S3 in file 7",FALSE,"S","IgG IgM","LFIA","indirect",45,274,100,347,71.994876420468,76.0961344798557,28.1321483871873,96.0351117415685
"3","Europe","England","National (REACT-2)","representative","9/15/2020","9/28/2020","2020-09-21",4,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-102",474,750,63.2,59.64,66.66,NA,"supplemental table S3 in file 7",FALSE,"S","IgG IgM","LFIA","indirect",45,554,157,725,69.2492386620518,73.7256059562104,21.0157088394647,96.4612018771746
"1","Europe","England","National (REACT-2)","representative","6/20/2020","7/13/2020","2020-07-01",2,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-14",277,341,81.23,76.68,85.24,NA,"supplemental table 3",FALSE,"S","IgG IgM","LFIA","indirect",44,270,124,329,75.8845425344386,79.2533726277827,36.8149222893528,96.189151014258
"4","Europe","England","National (REACT-2)","representative","10/27/2020","11/10/2020","2020-11-03",1,"Fortress Diagnostics LFIA COVID-19 total, Northern Ireland (recognizes spike)","n-15",1094,1765,61.98,59.67,64.25,NA,"table S2",FALSE,"S","IgG IgM","LFIA","indirect",44,1525,865,1725,82.8922232565007,86.3880297743117,49.0681970702598,97.6510436773084
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",39,44,88.64,75.44,96.21,"Yes","table 3",TRUE,"N","IgG IgM","LFIA","indirect",43,40,32,44,89.1554272046491,90.1965376979754,75.7470036088087,96.6196735327103
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",43,79,54.43,42.83,65.69,"Yes","table 3",TRUE,"N","IgG IgM","LFIA","indirect",43,70,42,78,85.5335116491191,88.8237614292277,54.3966317058727,98.249495586418
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",53,57,92.98,83,98.05,"Yes","table 2",TRUE,"N","IgG IgM","LFIA","indirect",42,53,44,57,91.8008295353004,92.7694471192144,80.4847006407511,97.6527379240903
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Biomerica anti-nucleocapsid IgG IgM rapid test","n-213",143,157,91.08,85.49,95.04,"Yes","table 3",TRUE,"N","IgG IgM","LFIA","indirect",42,140,119,152,88.5080603610538,89.2585945624891,77.3117442888956,95.5095319919585
"--","Latin America","Argentina","{ ? }","hospitalized + non-hospitalized patients","--","*September 2020","--",3,"COVIDAR anti-spike anti-RBD","n-224",113,137,82.48,75.06,88.44,"Yes","table 1",TRUE,"RBD, S","IgG IgM","ELISA","indirect",41,92,54,119,66.2476660920259,67.2569066914372,40.4378927824738,85.7449647960464
"1","Latin America","Argentina","Puerto Madryn","representative","03/03/2021","4/17/2021","2021-03-25",5,"COVIDAR anti-spike anti-RBD","n-248",57,78,73.08,61.84,82.5,NA,"positive on nasal swab (supplemental S2 data)",FALSE,"RBD, S","IgG IgM","ELISA","indirect",41,58,9,77,68.2544457314067,74.6703534146832,12.4145537190151,98.1838239343106
"--","Latin America","Argentina","{ ? }","hospitalized + non-hospitalized patients","--","*September 2020","--",1,"COVIDAR anti-spike anti-RBD","n-224",335,453,73.95,69.65,77.94,"Yes","table 1",TRUE,"RBD, S","IgG IgM","ELISA","indirect",40,396,345,427,86.8961257747489,87.4575445303755,76.7441189682488,93.7235306521981
"--","Latin America","Argentina","{ ? }","hospitalized + non-hospitalized patients","--","--","--",1,"COVIDAR anti-spike anti-RBD","n-227",252,289,87.2,82.79,90.82,"Yes","figure 1A",TRUE,"RBD, S","IgG IgM","ELISA","indirect",40,253,150,283,84.1398007897171,87.4165316690043,52.5589471938396,97.706540188358
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",4,"Abingdon AbC-19 IgG anti-spike","n-213",35,43,81.4,66.6,91.61,"Yes","table 3",TRUE,"S","IgG","LFIA","sandwich",39,33,20,40,74.3284392272438,75.6496315655796,50.8134404853432,90.0115963935918
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",6,"Abingdon AbC-19 IgG anti-spike","n-213",50,73,68.49,56.56,78.87,"Yes","table 3",TRUE,"S","IgG","LFIA","sandwich",39,51,16,70,66.5639880469116,69.5764832168235,22.5558465011909,94.4392751979731
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Abingdon AbC-19 IgG anti-spike","n-213",122,152,80.26,73.04,86.27,"Yes","table 3",TRUE,"S","IgG","LFIA","sandwich",38,130,106,144,84.7570278302231,85.5785572135329,70.8993079224427,93.8709287885508
"1","Europe","Switzerland","{ Vaud }","convenience (general population)","5/4/2020","6/27/2020","5/31/2020",2.5,"SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)","n-301",215,219,98.17,95.39,99.5,"","table 1 (not yet included in seroreversion paper)",TRUE,"S","IgG IgA","ELISA","indirect",37,192,100,216,83.4693909270165,87.7123929304335,46.1396615930044,98.3858147832712
"1","Europe","Switzerland","11 cantons","representative","*October 2020","*February 2021","2020-12-20",1,"SenASTrIS test (Sensitive Anti-SARS-CoV-2 Spike Trimer Immunoglobulin Serological)","n-299",128,143,89.51,83.29,94.01,NA,"table 1 (not yet in seroreversion paper nor in PRISMA list / tab)",FALSE,"S","IgG IgA","ELISA","indirect",36,135,101,143,92.265492590781,94.6418140788984,71.0923773428124,99.2468030782321
"2","Europe","Spain","National","representative","5/18/2020","6/1/2020","2020-05-25",2,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-104",276,360,76.67,71.95,80.94,NA,"tabla 6 (page 19)",FALSE,"S","IgG IgM","LFIA","indirect",35,317,169,355,84.0882584397303,88.1278846715681,47.3854337804575,98.3075427190452
"3","Europe","Spain","National","representative","6/8/2020","6/22/2020","2020-06-15",2,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-104",341,460,74.13,69.87,78.07,NA,"tabla 6 (page 19)",FALSE,"S","IgG IgM","LFIA","indirect",35,405,223,453,84.1940466801117,88.0999143968044,48.8808579134137,98.2914013032372
"4","Europe","Spain","National","representative","11/16/2020","11/29/2020","2020-11-22",2,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-45",1137,1777,63.98,61.7,66.22,NA,"tabla 8 (page 20)",FALSE,"S","IgG IgM","LFIA","indirect",35,1564,861.975,1747,84.1103115491103,88.0470741307537,48.5000948361338,98.2622384181696
"1","Europe","Spain","National","representative","4/27/2020","5/11/2020","2020-05-04",1,"Orient Gene Biotech COVID-19 IgG/IgM Rapid Test anti-spike","n-44",189,213,88.73,83.7,92.65,NA,"table 2",FALSE,"S","IgG IgM","LFIA","indirect",34,172,88,206,77.4659354326888,80.941946813147,41.6740223055679,96.295213966842
"1","North America","USA","Hillsborough County, unvaccinated population","representative","*October 2020","*March 2021","",7,"New York, Mount Sinai RBD ELISA","n-178",25,26,96.15,80.36,99.9,"N","",TRUE,"RBD, S","IgG","ELISA","indirect",33,25,22,26,96.5581807987749,97.4019570030531,88.6392864705879,99.5867650781911
"1","Europe","USA","Hillsborough County, unvaccinated population","representative","*October 2020","*March 2021","2021-01-01",4,"New York, Mount Sinai RBD ELISA","n-178",122,126,96.83,92.07,99.13,NA,"appendix table",FALSE,"RBD, S","IgG","ELISA","indirect",32,119,104,126,93.7988914630231,94.7067500678854,83.5475864122594,98.8628098195959
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*May 2021",13,"in-house THL Finland FMIA anti-spike assay","n-184",356,367,97,94.7,98.49,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,"S","IgG","CMIA","indirect",31,364,351,367,98.8308562842656,99.1422806150842,96.0319078047801,99.8286391926984
"--","Europe","Finland","{ 5 hospital districts }","convenience (general population)","--","--","*October 2020",8,"in-house THL Finland FMIA anti-spike assay","n-184",360,367,98.09,96.11,99.23,"Yes","5 districts listed in n-181 and are:  Uusimaa [contains Helsinki], Pirkanmaa, Pohjois-Pohjanmaa [a.k.a. North Ostrobothnia], Pohjois-Savo, Varsinais-Suomi",TRUE,"S","IgG","CMIA","indirect",30,351,329,362,95.1650749206916,95.5358618162592,90.2264148220655,98.1141273783376
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",2,"Biozek COVID-19 IgG/IgM rapid test","n-213",47,49,95.92,86.02,99.5,"Yes","table 2",TRUE,"N, RBD","IgG IgM","LFIA","indirect",29,47,40,49,93.9979987053689,94.6829879363171,85.7346965005642,98.4309781822007
"--","Europe","Scotland","{ ? }","hospitalized + non-hospitalized patients","*September 2020","*November 2020","--",1,"Biozek COVID-19 IgG/IgM rapid test","n-213",65,68,95.59,87.64,99.08,"Yes","table 2",TRUE,"N, RBD","IgG IgM","LFIA","indirect",28,65,58,68,94.3772861422577,94.9546865534528,86.9700319047685,98.4635221422554
"--","Oceania","New Zealand","{ Southern District Health Board region }","hospitalized + non-hospitalized patients","3/11/2020","4/5/2020","--",10,"Abbott Alinity SARS-CoV-2 IgG II Quant","n-198",36,37,97.3,85.84,99.93,"Yes","",TRUE,"RBD","IgG","CMIA","indirect",27,28,0,37,63.067219840976,75.4697869443264,0.939178757043726,99.9045803753475
"1","Europe","Lithuania","6 cities and municipalities","representative","8/10/2020","9/10/2020","2020-08-25",4,"AMP Rapid Test SARS-CoV-2 IgG/IgM","n-172",6,12,50,21.09,78.91,NA,"",FALSE,NA,"IgG IgM","LFIA","indirect",26,10,2,12,78.7731734624652,86.0738637894022,25.0162587657865,99.1795323939385
"1","North America","USA","National (COVIDVu)","representative","--","--","2020-10-30",3,"BioRad Platelia Total Antibody nucleocapsid","n-143",77,127,60.63,51.57,69.18,NA,"",FALSE,"N","IgG IgM IgA","ELISA","sandwich",25,110,41,126,80.9607111916945,87.0801635527205,32.7864993994265,98.9576590911381
"2","North America","Canada","National (CCAHS), unvaccinated population","representative","11/2/2020","4/30/2021","2021-01-30",2,"CCAHS ELISA anti-spike anti-RBD anti-nucleocapsid (positive on at least 2 out of 3)","n-261",115,145,79.31,71.8,85.58,NA,"table 1",FALSE,"N, RBD, S","IgG","CMIA","indirect",24,127,58,144,82.9403057096675,87.9883114837534,41.0287837088427,98.7465183821727
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"EDI Novel coronavirus COVID19 IgG anti-nucleocapsid","n-165",15,58,25.86,15.26,39.04,"Yes","",TRUE,"N","IgG","ELISA","indirect",23,47,2,58,68.8566051971263,81.467781100724,3.35872150903034,99.8111645304918
"1","South Asia","India","West Bengal: Paschim Medinipur","representative","7/27/2020","8/7/2020","8/1/2020",2,"ERBALISA COVID-19 IgG","n-95",11,30,36.67,19.93,56.14,"Yes","",TRUE,"N, S","IgG","ELISA","indirect",22,27,12,30,83.616091791561,88.3163325433429,43.1852058574127,98.7330019264371
"3","South Asia","India","Delhi","representative","9/1/2020","9/7/2020","2020-09-04",2,"ERBALISA COVID-19 IgG","n-83",148,226,65.49,58.9,71.67,NA,"",FALSE,"N, S","IgG","ELISA","indirect",22,200,94,224,83.5882131501239,88.4767293075847,41.8539874386886,98.6894807393177
"4","South Asia","India","Delhi","representative","10/15/2020","10/21/2020","2020-10-18",2,"ERBALISA COVID-19 IgG","n-83",147,260,56.54,50.28,62.65,NA,"",FALSE,"N, S","IgG","ELISA","indirect",22,230,109,257,83.4926087225925,88.2985486182996,42.4463821551662,98.6983020182739
"1","Europe","Spain","Cantabria","representative","4/27/2020","5/29/2020","2020-05-13",1,"Hangzhou Clongene IgM/IgG rapid test","n-46",2,3,66.67,9.43,99.16,NA,"table 1, used only IgG",FALSE,NA,"IgG","LFIA","indirect",21,3,1,3,84.8375970358162,88.8956136154072,48.661541523186,98.648081497971
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"IDK (Immundiagnostik) anti-spike IgG","n-222",323,363,88.98,85.3,92.01,"Yes","supplementary table S2",TRUE,"S","IgG","ELISA","indirect",20,308,53,361,75.7778617429549,84.8850626838569,14.6341222536717,99.4147774238485
"1","Africa","Tunisia","El Omrane + La Goulette","representative","*March 2021","*April 2021","2021-04-01",3,"in-house ELISA for N protein and S protein from IPT (Institut Pasteur in Tunis)","n-196",56,73,76.71,65.35,85.81,NA,"table 3",FALSE,"N, RBD","IgG","ELISA",NA,19,63,22,73,80.7167155036007,86.8412427673345,31.3248211450293,98.9237955700702
"1","Africa","South Africa","Gauteng","representative","11/4/2020","1/22/2021","2020-12-13",5,"in-house Luminex S protein trimer IgG","n-99",57,122,46.72,37.64,55.97,NA,"",FALSE,"RBD","IgG","CMIA",NA,18,104,19,122,76.3279684214082,85.2009411040011,15.7061294403875,99.4212019847895
"--","South Asia","India","{ Delhi }","hospitalized + non-hospitalized patients","--","--","12/18/2020",2,"in-house RBD ELISA (Mehdi et al.)","n-162",568,672,84.52,81.56,87.18,"N (excluded, non-commercial assay not used in a seroprevalence study)","",TRUE,"RBD","IgG","ELISA","indirect",17,591,270,665,82.8353623101832,87.870115606655,40.2156091736212,98.7825730728948
"--","East Asia","South Korea","{ ? }","non-hospitalized patients","--","--","--",8,"InBios SCoV-2 Detect IgG anti-spike ELISA","n-165",50,58,86.21,74.62,93.85,"Yes","",TRUE,"S","IgG","ELISA","indirect",16,47,1,58,68.7365421118982,81.3549527263236,3.06847516954536,99.812122240939
"2","South Asia","India","Delhi","representative","8/1/2020","8/7/2020","2020-08-04",1,"Kavach-AntiSARS-CoV-2 IgG ELISA (Zydus)","n-83",232,356,65.17,59.97,70.11,NA,"",FALSE,"N, RBD, S","IgG","ELISA","indirect",15,317,172,352,85.0497559884312,89.1025790956397,48.8540989508301,98.6136594343102
"2","Europe","USA","Los Angeles County, unvaccinated population","representative","4/9/2021","4/25/2021","2021-04-17",4,"Luminex xMAP for spike and nucleocaspid (Los Angeles study used RBD portion)","n-174",57,59,97,90.3,99.1,NA,"table 2",FALSE,"RBD","IgG","CMIA","indirect",14,50,13,59,78.0916707183027,85.3393450412381,23.6089034694459,99.1652007519388
"1","Europe","USA","Holyoke","representative","11/5/2020","12/31/2020","2020-12-03",2,"Massachusetts General Hospital, anti-spike ELISA","n-78",12,18,66.67,40.99,86.66,NA,"figure 2C",FALSE,"RBD","IgG","ELISA","indirect",13,16,7,18,83.0746270415771,88.0300686842442,40.4828428721492,98.7950796595612
"--","North America","USA","{ ? }","non-hospitalized patients","--","--","--",3,"Siemens SARS-CoV-2 Total Advia Centaur","n-134",40,41,97.56,87.14,99.94,"Yes","",TRUE,"RBD","IgG IgM","CMIA","sandwich",12,35,12,41,80.5328152465465,86.52161076853,31.7648797891584,98.9211307633664
"1","Europe","Portugal","National (Castro et al.)","convenience (general population)","9/8/2020","10/14/2020","2020-09-26",3,"Siemens SARS-CoV-2 Total Advia Centaur","n-155",112,136,82.35,74.89,88.35,NA,"appendix 11",FALSE,"RBD","IgG IgM","CMIA","sandwich",12,118,42,135,80.4266011297183,86.5930966011078,31.556896786527,98.970389554207
"--","North America","Canada","{ Toronto and Peel }","hospitalized + non-hospitalized patients","--","--","--",2.5,"Sinai Health (Toronto) anti-spike ELISA","n-169",22,22,100,84.56,100,"Yes","figure 3",TRUE,"S","IgG","CMIA","indirect",11,19,7,22,81.631393024099,87.1327844339327,36.013087899423,98.7967512913121
"1","Latin America","Peru","Lima Metropolitana (provinces of Lima + Callao)","representative","6/28/2020","7/9/2020","2020-07-03",1,"Standard Q COVID-19 IgM/IgG Plus","k-15",77,84,91.67,83.58,96.58,NA,"table S9",FALSE,"N, RBD","IgG IgM","LFIA","indirect",10,75,38,84,84.6604973837622,89.0528961751891,46.2664401423891,98.6583908032785
"1","Middle East","Lebanon","National","representative","12/7/2020","1/15/2021","2020-12-26",2,"Techno Genetics anti-RBD, nCOVID-19 IgG/IgM POCT (point-of-care test)","n-150",38,60,63.33,49.9,75.41,NA,"table 3",FALSE,"RBD","IgG IgM","LFIA","indirect",9,53,23,60,83.0738358888461,87.9957661682747,39.9434042771959,98.7567930002735
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-nucleocapsid IgG with AIA-CL1200","n-167",314,376,83.51,79.37,87.12,"Yes","",TRUE,"N","IgG","CMIA","indirect",8,314,33,375,72.9846311735567,83.3292107908331,9.21053868228685,99.6249140324314
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-nucleocapsid total Ig with AIA-CL1200","n-167",365,376,97.07,94.83,98.53,"Yes","",TRUE,"N","IgG IgM IgA etc.","CMIA","sandwich",7,312,32,375,72.4372899599853,82.9502905967317,8.68036309623312,99.578282245558
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-spike IgG with AIA-CL1200","n-167",344,376,91.49,88.2,94.11,"Yes","",TRUE,"RBD","IgG","CMIA","indirect",6,312,32,375,72.6042088599783,82.8536118613738,8.90937179419242,99.5911078664495
"--","East Asia","Japan","{ ? }","convenience (general population)","9/2/2020","10/26/2020","9/29/2020",6,"Tosoh anti-spike total Ig with AIA-CL1200","n-167",369,376,98.14,96.2,99.25,"Yes","",TRUE,"RBD","IgG IgM IgA etc.","CMIA","sandwich",5,311,34,375,72.7973734038488,82.7095327390287,9.26165520536271,99.5145399870673
"--","Europe","Germany","{ Cologne }","hospitalized + non-hospitalized patients","*August 2020","*September 2020","--",5,"Abbott Alinity i SARS-CoV-2 IgG nucleocapsid","n-222",195,363,53.72,48.44,58.94,"Yes","supplementary table S2",TRUE,"N","IgG","CMIA","indirect",4,286,52.9750000000001,359,71.4301551053464,78.6815618098369,14.8016707397224,98.7209451890398
"--","Europe","Ireland","{ Dublin }","hospitalized + non-hospitalized patients","3/26/2020","7/10/2020","5/18/2020",1,"Abbott Alinity i SARS-CoV-2 IgG nucleocapsid","n-225",149,185,80.54,74.09,85.98,"Yes","table 3",TRUE,"N","IgG","CMIA","indirect",3,155,77,181,79.957893971418,83.7695447954192,42.532705910148,97.242801049915
"--","North America","USA","{ Arkansas }","non-hospitalized patients","9/12/2020","10/24/2020","2020-10-03",2,"Beckman ACCESS SARS-CoV-2 anti-RBD","n-281",14,17,82.35,56.57,96.2,NA,"supplementary table 1 and table 1",FALSE,"RBD","IgG","CLIA","indirect",2,15,9,17,83.0812374799776,84.9643567000037,58.6503744904294,96.5015960201575
"--","North America","USA","{ Arkansas }","non-hospitalized patients","11/7/2020","12/19/2020","2020-11-28",2,"Beckman ACCESS SARS-CoV-2 anti-RBD","n-281",4,8,50,15.7,84.3,NA,"supplementary table 1 and table 1",FALSE,"RBD","IgG","CLIA","indirect",2,7,4,8,83.0812374799776,84.9643567000037,58.6503744904294,96.5015960201575
"--","North America","USA","{ Arkansas }","non-hospitalized patients","8/15/2020","9/5/2020","2020-08-25",1,"Beckman ACCESS SARS-CoV-2 anti-RBD","n-281",10,12,83.33,51.59,97.91,NA,"supplementary table 1 and table 1",FALSE,"RBD","IgG","CLIA","indirect",1,10,6,12,77.584435625018,78.3996871180946,60.7309623422019,90.1669654534844
